Preemptive versus prophylactic approaches in the management of cytomegalovirus disease in solid organ transplant recipients: What we know and what we do not know

Clinical Infectious Diseases

Volumn 43, Issue 7, 2006, Pages 881-883

  Meylan, Pascal R A ^a,b   Pascual, Manuel ^a  

^a Centre de Transplantation d'Organes   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; VALACICLOVIR; VALGANCICLOVIR; ANTIVIRUS AGENT;

ANTIBIOTIC PROPHYLAXIS; CALCULATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DATA ANALYSIS; DRUG EFFECT; DRUG EFFICACY; GRAFT RECIPIENT; HUMAN; INFECTION RISK; NOTE; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREEMPTIVE THERAPY; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZATION; VIRUS REPLICATION; CYTOMEGALIC INCLUSION BODY DISEASE; OPPORTUNISTIC INFECTION; PREVENTIVE MEDICINE; TRANSPLANTATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; PREVENTIVE MEDICINE; TRANSPLANTATION;

EID: 33748674217     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/507338     Document Type: Note

References (19)

1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338:1741-51.
2. Gane E, Saliba F, Valdecasas GJC, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997; 350:1729-33.
3. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340:1462-70.
4. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4:611-20.
5. Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 2001; 32:742-51.
6. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis 2005; 40:704-8.
7. Snydman DR. Counterpoint: prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: the case for prophylaxis. Clin Infect Dis 2005; 40:709-12.
8. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5:218-27.
9. Cytomegalovirus. Am J Transplant 2004; 4:51-8.
10. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989; 261:3607-9.
11. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3:731-5.
12. Small LN, Lau J, Snydman DR. Preventing post-organ transplant cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43:869-80 (in this issue).
13. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143:870-80.
14. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365:2105-15.
15. Strippoli GF, Hodson EM, Jones C, Craig JC. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006; 81:139-45.
16. Paya CV, Wilson JA, Espy MJ, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185:854-60.
17. Singh N. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. J Clin Virol 2006; 35:474-7.
18. Muheim C, Vogel G, Seydoux C, et al. Determinants of protracted cytomegalovirus infection in solid-organ transplant patients. Transplantation 2002; 74:226-36.
19. Valantine HA, Gao SZ, Menon SG, et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999; 100:61-6.